314 related articles for article (PubMed ID: 38112998)
21. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
22. N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications.
Wang L; Tang Y
Biomed Pharmacother; 2023 Jul; 163():114846. PubMed ID: 37167725
[TBL] [Abstract][Full Text] [Related]
23. Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog.
Ye T; Li J; Sun Z; Liu Y; Kong L; Zhou S; Tang J; Wang J; Xing HR
Cancer Med; 2019 Mar; 8(3):1232-1245. PubMed ID: 30740909
[TBL] [Abstract][Full Text] [Related]
24. An alginate-based platform for cancer stem cell research.
Qiao SP; Zhao YF; Li CF; Yin YB; Meng QY; Lin FH; Liu Y; Hou XL; Guo K; Chen XB; Tian WM
Acta Biomater; 2016 Jun; 37():83-92. PubMed ID: 27109764
[TBL] [Abstract][Full Text] [Related]
25. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
26. m
Cui Q; Shi H; Ye P; Li L; Qu Q; Sun G; Sun G; Lu Z; Huang Y; Yang CG; Riggs AD; He C; Shi Y
Cell Rep; 2017 Mar; 18(11):2622-2634. PubMed ID: 28297667
[TBL] [Abstract][Full Text] [Related]
27. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.
De Francesco EM; Sotgia F; Lisanti MP
Biochem J; 2018 May; 475(9):1611-1634. PubMed ID: 29743249
[TBL] [Abstract][Full Text] [Related]
28. Bench to Bedside: New Therapeutic Approaches with Extracellular Vesicles and Engineered Biomaterials for Targeting Therapeutic Resistance of Cancer Stem Cells.
Ingavle G; Das M
ACS Biomater Sci Eng; 2022 Nov; 8(11):4673-4696. PubMed ID: 36194142
[TBL] [Abstract][Full Text] [Related]
29. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.
Ryoo IG; Lee SH; Kwak MK
Oxid Med Cell Longev; 2016; 2016():2428153. PubMed ID: 26682001
[TBL] [Abstract][Full Text] [Related]
30. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.
van Vlerken LE; Kiefer CM; Morehouse C; Li Y; Groves C; Wilson SD; Yao Y; Hollingsworth RE; Hurt EM
Stem Cells Transl Med; 2013 Jan; 2(1):43-52. PubMed ID: 23283488
[TBL] [Abstract][Full Text] [Related]
31. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.
Li YR; Fang Y; Lyu Z; Zhu Y; Yang L
J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157
[TBL] [Abstract][Full Text] [Related]
32. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
33. microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities.
Asadzadeh Z; Mansoori B; Mohammadi A; Aghajani M; Haji-Asgarzadeh K; Safarzadeh E; Mokhtarzadeh A; Duijf PHG; Baradaran B
J Cell Physiol; 2019 Jul; 234(7):10002-10017. PubMed ID: 30537109
[TBL] [Abstract][Full Text] [Related]
34. Functional and Molecular Characters of Cancer Stem Cells Through Development to Establishment.
Afify SM; Hassan G; Ishii H; Monzur S; Nawara HM; Osman A; Abu Quora HA; Sheta M; Zahra MH; Seno A; Seno M
Adv Exp Med Biol; 2022; 1393():83-101. PubMed ID: 36587303
[TBL] [Abstract][Full Text] [Related]
35. New Opportunities and Challenges to Defeat Cancer Stem Cells.
Ramos EK; Hoffmann AD; Gerson SL; Liu H
Trends Cancer; 2017 Nov; 3(11):780-796. PubMed ID: 29120754
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
Liang Z; Kidwell RL; Deng H; Xie Q
Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
[TBL] [Abstract][Full Text] [Related]
37. Cancer Stem Cells: Root of the Evil.
Erkisa M; Karakas D; Ulukaya E
Crit Rev Oncog; 2019; 24(1):69-87. PubMed ID: 31679222
[TBL] [Abstract][Full Text] [Related]
38. The epitranscriptome in stem cell biology and neural development.
Vissers C; Sinha A; Ming GL; Song H
Neurobiol Dis; 2020 Dec; 146():105139. PubMed ID: 33065280
[TBL] [Abstract][Full Text] [Related]
39. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
40. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
